ABSTRACT
BACKGROUND: The aim of this research is to develop a scale that will evaluate the knowledge, attitudes and behaviors of employees about COVID-19 and to test its validity and reliability. METHODOLOGY: The methodological type of research was used between August-November 2020, under observation in organized industrial zones. Information was collected from a total of 543 employees. Confirmatory factor analysis and correlation analysis were performed for the value, item-total correlations and construct validity. SPSS 25.0 (IBM Inc., Armonk, NY, USA), Jasp 0.14 (University of Amsterdam) and Lisrel 9.1(Scientific Software International, Inc., Chapel Hill, NC, USA) programs were used in the analysis. RESULTS: 83.1% of the participants in the study are male, the average age is 37.4 ± 8.0, 76.1% are married, and 49.4% are high school graduates. The Cronbach alpha value of the COVID-19 information part is 0.86 in total, the contamination information dimension is 0.71 and the protection information dimension is 0.84. The COVID-19 attitude section consists of four sub-dimensions and 13 items classified within the framework of the health belief model. In summary, the goodness of fit values for the knowledge, attitude and behavior sections, respectively, are: RMSEA values 0.05, 0.03 and 0.04; CFI values 0.98, 0.98 and 0.99; GFI values 0.97, 0.97 and 0.99. CONCLUSIONS: It has been determined that the internal consistency of the COVID-19 knowledge, attitude and behavior scale conducted on employees is high and compatible, and its validity findings are sufficient. The scale is recommended as an applicable tool to measure COVID-19 knowledge, attitudes and behaviors.
ABSTRACT
Limited data are available on the short- to midterm levels of antibodies to the CoronaVac vaccine and quantitative change in humoral response after homologous or heterologous booster doses. In this prospective cohort study, we evaluated the anti-receptor-binding domain (RBD) immunoglobulin G (IgG) levels after two doses of CoronaVac and heterologous/homologous booster administration among healthcare workers in a university hospital in Turkey. Quantitative anti-RBD IgG antibody levels were measured at first and fourth months in 560 healthcare workers who had completed two doses of CoronaVac vaccine, and within 2 months after the third dose of CoronaVac or BNT162b2. Participants were asked to complete a questionnaire during the first blood draw. The seropositivity rate was 98.9% and 89.1%, and the median antibody level was 469.2 AU/ml and 166.5 AU/ml at first and fourth month, respectively. In the fourth month, a mean reduction of 61.4% ± 20% in antibody levels was observed in 79.8% of the participants. The presence of chronic disease (odds ratio [OR]: 1.76, 95% confidence interval [CI]: 1.15-2.69) and being in the 36-50 age group (OR: 2.11, 95% CI: 1.39-3.19) were identified as independent predictors for low antibody response. The antibody level increased 104.8-fold (median: 17 609.4 vs. 168 AU/ml) and 8.7-fold (median: 1237.9 vs. 141.4 AU/ml) in the participants who received BNT162b2 and CoronaVac, respectively. During the follow-up, 25 healthcare workers (4.5%) were infected with severe acute respiratory syndrome coronavirus 2. Considering the waning immunity and circulating variants, a single booster dose of messenger RNA vaccine seems reasonable after the inactivated vaccine especially in risk groups.
Subject(s)
BNT162 Vaccine , COVID-19 , Antibodies, Viral , Antibody Formation , COVID-19/prevention & control , Health Personnel , Humans , Prospective Studies , Turkey , Vaccines, Synthetic , mRNA VaccinesABSTRACT
BACKGROUND: Healthcare workers (HCWs) have increased risk for SARS-CoV-2 infection via contacts in hospitals, as well as via transmission in the community. Serial interval, which is defined as the time between symptom onsets in an infector-infectee pair, and the incubation period are key parameters in determining the control strategies for COVID-19. This study aimed to evaluate surveillance of HCWs and estimate the serial interval and incubation period of COVID-19. METHODS: A total of 149 HCWs and 36 certain infector-infectee pairs between 19th March 2020 and 1st November 2020 in a university hospital were included in the study. Epidemiological characteristics were recorded. Serial interval and incubation period were estimated using parametric accelerated failure time models. RESULTS: Forty HCWs (26.8%) were detected via contact-based surveillance. Of 100 HCWs epidemiologically linked with a confirmed COVID-19 case, 36 (36%) had contact with a colleague. The median serial interval was 3.93 days (95% CI: 3.17-4.83). Of symptomatic HCWs, 97.5% had developed symptoms 13.71 (95% CI: 9.39-18.73) days after symptom onset of the primary case. The median incubation period was 3.99 (95% CI: 3.25-4.84) days. Of symptomatic HCWs, 97.5% developed symptoms within 9.49 (95% CI: 6.75-12.20) days after infection. CONCLUSIONS: The serial interval and the incubation period of COVID-19 in HCWs were shorter than in the general population. Rigorous contact tracing and isolation of infected HCWs could have resulted in shorter serial intervals. Implementation of more stringent in-hospital control measures focussed on transmission between HCWs should be considered.